Needham Reiterates Buy on TScan Therapeutics, Maintains $11 Price Target

Benzinga · 05/13 10:24
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11 price target.